COO

Business profile & competitive position

The Cooper Companies, Inc. (COO) is classified in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. That classification places it alongside companies that design, manufacture, and distribute regulated medical devices, diagnostic tools, and single-use or recurring consumables. Economics in this space depend on product reliability, regulatory approvals, customer switching costs, and long-term supply relationships with hospitals, clinics, and consumers.

The company’s current profitability metrics, however, are modest for a business typically viewed as a defensive healthcare name. COO’s net margin stands at 5.6%, while return on equity is 2.8%. A sub-3% ROE is well below the long-term cost of equity most investors demand and suggests that the capital invested in the business is not translating into strong shareholder returns at the moment. That combination—a thin bottom line and a low ROE—does not support a wide economic moat based purely on current returns. Any competitive strength would have to come from intangible factors common to the industry, such as regulatory clearances and customer retention, rather than from exceptional pricing power or asset efficiency right now.

Financial posture

COO currently carries a market capitalization of $14.5 billion and trades at a trailing P/E ratio of 62.9. Against a net margin of 5.6% and an ROE of 2.8%, that multiple is exceptionally high. In plain terms, the market is pricing in a large rebound or multi-year acceleration in earnings rather than paying for today’s profitability. A P/E above 60 while net margin is in the mid-single digits makes the valuation highly sensitive to small changes in growth or sentiment.

The stock’s beta is 0.84, meaning it has historically moved less than the overall market, which fits the healthcare/defensive sector profile. Low volatility can be attractive, but it also means a high starting valuation can compress quickly if results disappoint. With an ROE of just 2.8%, the company is either in an investment-heavy phase, digesting past acquisitions, or operating in sub-segments where returns are structurally lower. Either way, the financial posture is one of premium valuation supported more by future expectations than by current margins or capital efficiency.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies name, COO is exposed to the broad forces that shape the healthcare device industry rather than any single commodity cycle. The most relevant macro factors include regulatory oversight (FDA approvals, quality inspections, and recall risk), reimbursement policy (Medicare/Medicaid rates and private insurer coverage decisions), and trade policy (tariffs or logistics constraints on components sourced internationally). Currency translation can also matter: many medical-supply companies generate meaningful revenue outside the United States, so dollar strength can pressure reported results.

Supply-chain resiliency remains a sector-wide theme, particularly for products that depend on specialized plastics, silicone, sterilization capacity, or just-in-time manufacturing. Geopolitical instability can indirectly affect this group through shipping costs, component availability, and demand shifts in key overseas markets. Finally, the industry is sensitive to demographic trends—aging populations support long-term demand—but also to pricing pressure from generics, low-cost competitors, and hospital purchasing consortia. These are generic, industry-level exposures implied by the Medical - Instruments & Supplies classification.

Recent developments

The most COO-specific headline in the recent data is a zacks.com article dated August 5, 2026, titled “The Cooper Companies (COO) Upgraded to Buy: Here's What You Should Know.” That upgrade is a data point in sentiment rather than a fundamental result. It suggests at least one research house turned more constructive on the stock heading into late summer, but the article’s reasoning is not detailed in the available snapshot, so it should be read as a view, not a catalyst.

Outside of COO, the broader August 2026 earnings calendar produced several notable reports. On August 5, 2026, gurufocus.com published Q2 earnings call highlights for Assurant and Global Payments, while on August 6, 2026, gurufocus.com covered Motorola Solutions’ Q2 results. The Global Payments headline specifically cited “Strong EPS Growth and Strategic Progress Amid Middle East Headwinds,” a reminder that geopolitical risk can color even non-defense sectors. These reports do not directly affect COO’s fundamentals, but they set the tone of a Q2 reporting period where strong results coexisted with macro headwinds.

Earnings behavior & post-earnings drift

COO’s recent earnings history is unusual: the company has beaten consensus in each of the last 8 reported quarters, giving it a 100% beat rate, with an average earnings surprise of 4.6%. Yet the average 5-day price change after those reports is -0.91%, classified as a downward post-earnings drift. That disconnect—repeated beats but mild net selling pressure across the window—is the kind of pattern that suggests expectations matter as much as, or more than, the headline beat.

The last four quarterly reactions illustrate the volatility. On June 4, 2026, COO reported $1.21 versus a $1.11 estimate, a 10.0% surprise, and the stock rose 8.58% the next day and 8.85% over the following five days. The prior quarter, March 5, 2026, delivered $1.10 against $1.03, a 6.8% beat, yet the stock fell 4.55% the next day and 10.82% over five days. On December 4, 2025, a 3.6% beat ($1.15 vs. $1.11) produced a 5.67% one-day gain and 6.59% over five days, while on August 27, 2025, a 2.8% beat ($1.10 vs. $1.07) was met with a -12.86% one-day drop and -8.24% five-day decline. The market’s real expectation therefore appears to sit above the published Street number; a beat does not guarantee a rally, and the magnitude of surprise only loosely correlates with the direction of the move.

Looking ahead, COO’s next scheduled report is September 9, 2026, after the market close, with a consensus EPS estimate of $1.11. At a current price of $74.23, an RSI of 60.5, and a 50-day EMA of $70.31, the stock is heading into the report with positive near-term momentum but also a history of sharp two-way reactions after beats.

For a deeper dive into how institutional analysts are modeling revenue, margins, and the September 2026 quarter, it is worth reviewing the full institutional verdict on COO rather than relying on headline numbers alone.